WO2001072735A3 - Benzopyranes useful as tnf alpha inhibitors - Google Patents

Benzopyranes useful as tnf alpha inhibitors Download PDF

Info

Publication number
WO2001072735A3
WO2001072735A3 PCT/US2001/009897 US0109897W WO0172735A3 WO 2001072735 A3 WO2001072735 A3 WO 2001072735A3 US 0109897 W US0109897 W US 0109897W WO 0172735 A3 WO0172735 A3 WO 0172735A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf alpha
useful
benzopyranes
alpha inhibitors
novel compounds
Prior art date
Application number
PCT/US2001/009897
Other languages
French (fr)
Other versions
WO2001072735A2 (en
Inventor
Jie Fei Cheng
Thomas Arrhenius
Akira Ishikawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Jie Fei Cheng
Thomas Arrhenius
Akira Ishikawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Jie Fei Cheng, Thomas Arrhenius, Akira Ishikawa filed Critical Chugai Pharmaceutical Co Ltd
Priority to AU2001261006A priority Critical patent/AU2001261006A1/en
Publication of WO2001072735A2 publication Critical patent/WO2001072735A2/en
Publication of WO2001072735A3 publication Critical patent/WO2001072735A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel compounds of formula (I) capable of inhibiting TNF alpha and having antiinflammatory properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
PCT/US2001/009897 2000-03-28 2001-03-28 Benzopyranes useful as tnf alpha inhibitors WO2001072735A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001261006A AU2001261006A1 (en) 2000-03-28 2001-03-28 Benzopyranes useful as tnf alpha inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19270200P 2000-03-28 2000-03-28
US60/192,702 2000-03-28
US25503200P 2000-12-11 2000-12-11
US60/255,032 2000-12-11

Publications (2)

Publication Number Publication Date
WO2001072735A2 WO2001072735A2 (en) 2001-10-04
WO2001072735A3 true WO2001072735A3 (en) 2002-03-28

Family

ID=26888293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009897 WO2001072735A2 (en) 2000-03-28 2001-03-28 Benzopyranes useful as tnf alpha inhibitors

Country Status (2)

Country Link
AU (1) AU2001261006A1 (en)
WO (1) WO2001072735A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853530A1 (en) * 2013-09-25 2015-04-01 Université de Rennes 1 New PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof
KR101934651B1 (en) * 2017-10-19 2019-01-02 가톨릭대학교 산학협력단 Composition for Preventing or Treating TNF-mediated Disease Comprising Novel Derivatives and Method for Inhibiting TNF-activity with the Same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140830A2 (en) * 1983-08-31 1985-05-08 Zyma SA Pharmaceutical preparations containing flavene or thioflavene derivatives, the use thereof, novel flavenes and thioflavenes, and processes for their manufacture
WO1996040110A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Novel benzopyran compounds and methods for their use
EP0924207A1 (en) * 1996-08-27 1999-06-23 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140830A2 (en) * 1983-08-31 1985-05-08 Zyma SA Pharmaceutical preparations containing flavene or thioflavene derivatives, the use thereof, novel flavenes and thioflavenes, and processes for their manufacture
WO1996040110A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Novel benzopyran compounds and methods for their use
EP0924207A1 (en) * 1996-08-27 1999-06-23 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AUST. J. CHEM., vol. 21, no. 9, 1968, AUSTRALIA, pages 2247 - 54 *
CHEMICAL ABSTRACTS, vol. 69, no. 27, 1968, Columbus, Ohio, US; abstract no. 106434j, CLARK-LEWIS,J.W.: "FLAVAN DERIVATIVES.XXIII.PREPARATION A. SYNTHETIC APPLIC. OF 3-FLAVENES." page 9965; column 2; XP002182689 *
G.SARTORI ET AL.: "GEN. SYNTHESIS OF 2H-BENZO[B]PYRANS (CROM-3-ENES)", JOURNAL OF ORGANIC CHEMISTRY., vol. 44, no. 5, 1979, AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 803 - 5, XP002182687, ISSN: 0022-3263 *
Y.ASHIHARA ET AL.: "A NEW SYNTHESIS OF FLAVONES", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN., vol. 50, no. 12, 1977, JAPAN PUBLICATIONS TRADING CO. TOKYO., JP, pages 3298 - 3301, XP002182688, ISSN: 0009-2673 *

Also Published As

Publication number Publication date
WO2001072735A2 (en) 2001-10-04
AU2001261006A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
WO2001087882A3 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1084941A1 (en) Compounds and their use
HK1086485A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
EP1619180A4 (en) CaSR ANTAGONIST
GB0406282D0 (en) Therapeutic compounds
ATE386725T1 (en) HETEROCYCLYL COMPOUNDS
GB0222514D0 (en) Organic compounds
MXPA03010761A (en) Pharmaceutical combinations.
GB0109122D0 (en) Novel compounds
MXPA05010521A (en) Biphenyl carboxylic amide p38 kinase inhibitors.
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
NO304113B1 (en) Crystalline thiagabine hydrochloride monohydrate, pharmaceutical composition comprising it, and use thereof for the manufacture of a medicament
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
WO2004091591A3 (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP